

# Mehdi Taghipour

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/11604842/publications.pdf>

Version: 2024-02-01

25  
papers

699  
citations

516561

16  
h-index

580701

25  
g-index

25  
all docs

25  
docs citations

25  
times ranked

1128  
citing authors

#	ARTICLE	IF	CITATIONS
1	FDG-PET/CT and MRI for Evaluation of Pathologic Response to Neoadjuvant Chemotherapy in Patients With Breast Cancer: A Meta-Analysis of Diagnostic Accuracy Studies. <i>Oncologist</i> , 2016, 21, 931-939.	1.9	174
2	Diagnostic Accuracy of Follow-Up FDG PET or PET/CT in Patients With Head and Neck Cancer After Definitive Treatment: A Systematic Review and Meta-Analysis. <i>American Journal of Roentgenology</i> , 2015, 205, 629-639.	1.0	80
3	Classification of clinical significance of MRI prostate findings using 3D convolutional neural networks. <i>Proceedings of SPIE</i> , 2017, 10134, .	0.8	42
4	<sup>18</sup> F-FDG PET/CT: Therapy Response Assessment Interpretation (Hopkins Criteria) and Survival Outcomes in Lung Cancer Patients. <i>Journal of Nuclear Medicine</i> , 2016, 57, 855-860.	2.8	40
5	FDG PET/CT in Pancreatic and Hepatobiliary Carcinomas. <i>PET Clinics</i> , 2015, 10, 327-343.	1.5	36
6	Value of Intratumoral Metabolic Heterogeneity and Quantitative <sup>18</sup> F-FDG PET/CT Parameters to Predict Prognosis in Patients With HPV-Positive Primary Oropharyngeal Squamous Cell Carcinoma. <i>Clinical Nuclear Medicine</i> , 2017, 42, e227-e234.	0.7	34
7	Value of FDG PET/CT in Patient Management and Outcome of Skeletal and Soft Tissue Sarcomas. <i>PET Clinics</i> , 2015, 10, 375-393.	1.5	28
8	<sup>18</sup> F-FDG-PET/CT therapy assessment of locally advanced pancreatic adenocarcinoma. <i>Nuclear Medicine Communications</i> , 2016, 37, 231-238.	0.5	28
9	Investigating the role of DCE-MRI, over T2 and DWI, in accurate PI-RADS v2 assessment of clinically significant peripheral zone prostate lesions as defined at radical prostatectomy. <i>Abdominal Radiology</i> , 2019, 44, 1520-1527.	1.0	28
10	Use of <sup>18</sup> F-Fludeoxyglucose-Positron Emission Tomography/Computed Tomography for Patient Management and Outcome in Oropharyngeal Squamous Cell Carcinoma. <i>JAMA Otolaryngology - Head and Neck Surgery</i> , 2016, 142, 79.	1.2	27
11	Predictive role of PI-RADSV2 and ADC parameters in differentiating Gleason pattern 3+4 and 4+3 prostate cancer. <i>Abdominal Radiology</i> , 2019, 44, 279-285.	1.0	24
12	Value of Fluorodeoxyglucose PET/Computed Tomography Patient Management and Outcomes in Thyroid Cancer. <i>PET Clinics</i> , 2015, 10, 265-278.	1.5	20
13	<sup>18</sup> F-FDG PET/CT and Melanoma. <i>Clinical Nuclear Medicine</i> , 2016, 41, e403-e409.	0.7	18
14	The value of follow-up <sup>18</sup> F-FDG PET/CT in the management and prognosis of patients with HPV-positive oropharyngeal squamous cell carcinoma. <i>Journal of Medical Imaging and Radiation Oncology</i> , 2015, 59, 681-686.	0.9	17
15	FDG PET/CT in Patients With Head and Neck Squamous Cell Carcinoma After Primary Surgical Resection With or Without Chemoradiation Therapy. <i>American Journal of Roentgenology</i> , 2016, 206, 1093-1100.	1.0	16
16	Molecular Imaging and Precision Medicine. <i>PET Clinics</i> , 2017, 12, 105-118.	1.5	16
17	<sup>18</sup> F-FDG PET/CT and Colorectal Cancer: Value of Fourth and Subsequent Posttherapy Follow-up Scans for Patient Management. <i>Journal of Nuclear Medicine</i> , 2015, 56, 989-994.	2.8	15
18	FDG Avidity and Tumor Burden: Survival Outcomes for Patients With Recurrent Breast Cancer. <i>American Journal of Roentgenology</i> , 2016, 206, 846-855.	1.0	15

#	ARTICLE	IF	CITATIONS
19	JOURNAL CLUB: Value of Quantitative FDG PET/CT Volumetric Biomarkers in Recurrent Colorectal Cancer Patient Survival. American Journal of Roentgenology, 2016, 207, 257-265.	1.0	15
20	Clinical Indications and Impact on Management: Fourth and Subsequent Posttherapy Follow-up <sup>18</sup> F-FDG PET/CT Scans in Oncology Patients. Journal of Nuclear Medicine, 2017, 58, 737-743.	2.8	10
21	Follow-up FDG PET/CT in Patients With Non-Hodgkin Lymphoma. Clinical Nuclear Medicine, 2016, 41, e93-e97.	0.7	4
22	Post-treatment <sup>18</sup> F-FDG-PET/CT versus contrast-enhanced CT in patients with oropharyngeal squamous cell carcinoma. Nuclear Medicine Communications, 2017, 38, 250-258.	0.5	4
23	The value of fourth and subsequent post-treatment <sup>18</sup> F-FDG PET/CT scans in the management of patients with non-Hodgkin's lymphoma. Nuclear Medicine Communications, 2016, 37, 699-704.	0.5	3
24	Utilizing dual energy CT to distinguish blood from contrast leakage following middle meningeal artery embolization for chronic subdural hematomas. Journal of NeuroInterventional Surgery, 2021, 13, 964-967.	2.0	3
25	Value of fourth and subsequent post-therapy follow-up <sup>18</sup> F-FDG PET/CT scans in patients with breast cancer. Nuclear Medicine Communications, 2016, 37, 602-608.	0.5	2